Clinical trial
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
NCT05098509 is registered in ClinicalTrials.gov with Radius Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
- Lead sponsor
- Radius Pharmaceuticals, Inc.
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- April 13, 2022
- Completion date
- October 31, 2022
- Enrollment
- 4 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.